John Quisel Sells 34,000 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) CEO John Quisel sold 34,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $70.21, for a total value of $2,387,140.00. Following the completion of the transaction, the chief executive officer owned 226,064 shares of the company’s stock, valued at approximately $15,871,953.44. The trade was a 13.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Disc Medicine Trading Up 0.0%

NASDAQ IRON opened at $70.47 on Thursday. The firm has a market capitalization of $2.69 billion, a PE ratio of -10.64 and a beta of 0.93. The stock’s 50 day moving average is $68.80 and its 200 day moving average is $71.18. Disc Medicine, Inc. has a twelve month low of $40.00 and a twelve month high of $99.50. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). Research analysts forecast that Disc Medicine, Inc. will post -6.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Seven Fleet Capital Management LP bought a new stake in shares of Disc Medicine during the first quarter valued at approximately $207,000. Bank of America Corp DE raised its holdings in Disc Medicine by 22.6% in the 1st quarter. Bank of America Corp DE now owns 166,775 shares of the company’s stock worth $10,664,000 after acquiring an additional 30,789 shares during the last quarter. California State Teachers Retirement System lifted its position in Disc Medicine by 47.8% in the 1st quarter. California State Teachers Retirement System now owns 34,382 shares of the company’s stock valued at $2,198,000 after acquiring an additional 11,126 shares in the last quarter. SummitTX Capital L.P. bought a new position in Disc Medicine in the 1st quarter valued at approximately $884,000. Finally, Octagon Capital Advisors LP purchased a new stake in Disc Medicine during the 1st quarter valued at $17,264,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Truist Financial lowered their price target on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Morgan Stanley upped their price objective on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Wall Street Zen upgraded shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Finally, Wells Fargo & Company lifted their target price on shares of Disc Medicine from $78.00 to $79.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Disc Medicine currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.80.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.